Apogee Therapeutics Inc. (NASDAQ:APGE) Shares Bought by Bank of New York Mellon Corp

Bank of New York Mellon Corp raised its holdings in shares of Apogee Therapeutics Inc. (NASDAQ:APGE - Free Report) by 93.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 214,231 shares of the company's stock after purchasing an additional 103,404 shares during the quarter. Bank of New York Mellon Corp owned 0.48% of Apogee Therapeutics worth $8,004,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in APGE. Ameriprise Financial Inc. purchased a new position in shares of Apogee Therapeutics in the 4th quarter worth approximately $259,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Apogee Therapeutics by 4.1% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,835 shares of the company's stock worth $1,078,000 after buying an additional 931 shares during the last quarter. Rhumbline Advisers grew its position in shares of Apogee Therapeutics by 3.2% in the 1st quarter. Rhumbline Advisers now owns 54,385 shares of the company's stock worth $2,032,000 after buying an additional 1,665 shares during the last quarter. BNP Paribas Financial Markets purchased a new position in shares of Apogee Therapeutics in the 4th quarter worth approximately $219,000. Finally, GAMMA Investing LLC grew its position in shares of Apogee Therapeutics by 3,560.1% in the 1st quarter. GAMMA Investing LLC now owns 5,417 shares of the company's stock worth $202,000 after buying an additional 5,269 shares during the last quarter. Institutional investors own 79.04% of the company's stock.

Insider Transactions at Apogee Therapeutics

In related news, insider Carl Dambkowski sold 10,090 shares of the stock in a transaction on Wednesday, July 2nd. The shares were sold at an average price of $45.09, for a total transaction of $454,958.10. Following the sale, the insider directly owned 238,998 shares of the company's stock, valued at approximately $10,776,419.82. This represents a 4.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders have sold 15,540 shares of company stock worth $653,093 over the last quarter. Corporate insiders own 42.77% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Guggenheim reaffirmed a "buy" rating and issued a $116.00 price objective on shares of Apogee Therapeutics in a research report on Wednesday, July 2nd. Wedbush reissued an "outperform" rating and set a $90.00 target price on shares of Apogee Therapeutics in a research report on Monday, July 7th. Citigroup reissued a "buy" rating on shares of Apogee Therapeutics in a research report on Monday, July 7th. Finally, BTIG Research boosted their target price on shares of Apogee Therapeutics from $100.00 to $115.00 and gave the stock a "buy" rating in a research report on Monday, July 7th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $99.00.

Apogee Therapeutics Trading Down 2.0%

Shares of APGE stock traded down $0.82 during trading hours on Friday, hitting $40.82. The company's stock had a trading volume of 600,248 shares, compared to its average volume of 1,298,459. The company has a 50 day moving average of $40.43 and a 200 day moving average of $38.20. The stock has a market cap of $1.88 billion, a PE ratio of -11.34 and a beta of 1.47. Apogee Therapeutics Inc. has a 12-month low of $26.20 and a 12-month high of $63.50.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.95) EPS for the quarter, beating the consensus estimate of ($1.19) by $0.24. As a group, analysts anticipate that Apogee Therapeutics Inc. will post -3.09 earnings per share for the current fiscal year.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.